Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Biswas, Sumi ^a   Choudhary, Prateek ^a   Elias, Sean C ^a   Miura, Kazutoyo ^b   Milne, Kathryn H ^a   De Cassan, Simone C ^a   Collins, Katharine A ^a   Halstead, Fenella D ^a   Bliss, Carly M ^a   Ewer, Katie J ^a   Osier, Faith H ^c   Hodgson, Susanne H ^a   Duncan, Christopher J A ^a   O'Hara, Geraldine A ^a   Long, Carole A ^b   Hill, Adrian V S ^a   Draper, Simon J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

AMA1 ANTIGEN; CHIMPANZEE ADENOVIRUS VECTOR SEROTYPE 63; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN G4 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MALARIA VACCINE; ME TRAP ANTIGEN; MODIFIED VACCINIA VIRUS VECTOR ANKARA; MSP1 ANTIGEN; UNCLASSIFIED DRUG; VIRUS VECTOR; IMMUNOGLOBULIN G; PARASITE ANTIGEN; PROTOZOON ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ANTIMICROBIAL ACTIVITY; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; EXPOSURE; GROWTH INHIBITION; HUMAN; IMMUNIZATION; IN VITRO STUDY; MALARIA; MALARIA CONTROL; MEROZOITE; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMODIUM FALCIPARUM; ADENOVIRIDAE; ADVERSE EFFECTS; ANIMAL; BIOSYNTHESIS; BLOOD; CLINICAL TRIAL; ENVIRONMENTAL EXPOSURE; GENETICS; HUMORAL IMMUNITY; IMMUNOLOGY; MALARIA, FALCIPARUM; PAN TROGLODYTES; PARASITOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHYSIOLOGY; PROCEDURES; SPECIES DIFFERENCE; VACCINATION; VACCINIA VIRUS;

ADENOVIRIDAE; PLASMODIUM FALCIPARUM;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BLOOD; ENVIRONMENTAL EXPOSURE; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; MALARIA VACCINES; MALARIA, FALCIPARUM; PAN TROGLODYTES; PLASMODIUM FALCIPARUM; SPECIES SPECIFICITY; VACCINATION; VACCINIA VIRUS;

EID: 84907463083     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107903     Document Type: Article

References (83)

1. Hill AV (2011) Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci 366: 2806-2814.
2. Murray CJ, Rosenfeld LC, Lim S.S., Andrews KG, Foreman KJ, et al. (2012) Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379: 413-431.
3. Alonso PL, Tanner M (2013) Public health challenges and prospects for malaria control and elimination. Nat Med 19: 150-155.
4. Langhorne J, Ndungu FM, Sponaas A.M., Marsh K (2008) Immunity to malaria: more questions than answers. Nat Immunol 9: 725-732.
5. Goodman AL, Draper SJ (2010) Blood-stage malaria vaccines - recent progress and future challenges. Ann Trop Med Parasitol 104: 189-211.
6. Holder AA (2009) The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. Parasitology 136: 1445-1456.
7. Remarque EJ, Faber BW, Kocken C.H., Thomas AW (2008) Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol 24: 74-84.
8. Draper SJ, Goodman AL, Biswas S, Forbes E.K., Moore AC, et al. (2009) Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria. Cell Host Microbe 5: 95-105.
9. Silvie O, Franetich JF, Charrin S, Mueller M.S., Siau A., et al. (2004) A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem 279: 9490-9496.
10. Ogutu BR, Apollo OJ, McKinney D, Okoth W., Siangla J, et al. (2009) Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One 4: e4708.
11. Spring MD, Cummings JF, Ockenhouse C.F., Dutta S., Reidler R, et al. (2009) Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS ONE 4: e5254.
12. Thera MA, Doumbo OK, Coulibaly D, Laurens M.B., Ouattara A., et al. (2011) A field trial to assess a blood-stage malaria vaccine. N Engl J Med 365: 1004-1013.
13. Good MF, Engwerda C (2011) Defying malaria: Arming T cells to halt malaria. Nat Med 17: 49-51.
14. Draper SJ, Heeney JL (2010) Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 8: 62-73.
15. Capone S, D'Alise AM, Ammendola V, Colloca S., Cortese R, et al. (2013) Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev Vaccines 12: 379-393.
16. Gilbert SC (2013) Clinical development of Modified Vaccinia virus Ankara vaccines. Vaccine 31: 4241-4246.
17. de Cassan SC, Draper SJ (2013) Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets. Expert Rev Vaccines 12: 365-378.
18. Draper SJ, Cottingham MG, Gilbert SC (2013) Utilizing poxviral vectored vaccines for antibody induction-Progress and prospects. Vaccine 31: 4223-4230.
19. Sheehy SH, Duncan CJ, Elias S.C., Collins KA, Ewer KJ, et al. (2011) Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors. Mol Ther 19: 2269-2276.
20. Sheehy SH, Duncan CJ, Elias S.C., Biswas S., Collins KA, et al. (2012) Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors. PLoS One 7: e31208.
21. Sheehy SH, Duncan CJ, Elias S.C., Choudhary P., Biswas S, et al. (2012) ChAd63-MVA-vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans. Mol Ther 20: 2355-2368.
22. Ewer KJ, O'Hara GA, Duncan CJ, Collins K.A., Sheehy SH, et al. (2013) Protective CD8(+) T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 4: 2836.
23. Goodman AL, Blagborough AM, Biswas S, Wu Y., Hill AV, et al. (2011) A Viral Vectored Prime-Boost Immunization Regime Targeting the Malaria Pfs25 Antigen Induces Transmission-Blocking Activity. PLoS ONE 6: e29428.
24. Borthwick N, Ahmed T, Ondondo B., Hayes P, Rose A, et al. (2014) Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1. Mol Ther 22: 464-475.
25. Barnes E, Folgori A, Capone S., Swadling L, Aston S, et al. (2012) Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 4: 115ra111.
26. Maroof A, Brown N, Smith B., Hodgkinson MR, Maxwell A, et al. (2012) Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis. J Infect Dis 205: 853-863.
27. Elias SC, Choudhary P, de Cassan SC, Biswas S, Collins KA, et al. (2014) Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection. Immunology 141: 628-644.
28. Elias SC, Collins KA, Halstead F.D., Choudhary P., Bliss CM, et al. (2013) Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection. J Immunol 190: 1135-1147.
29. O'Hara GA, Duncan CJ, Ewer K.J., Collins KA, Elias SC, et al. (2012) Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector. J Infect Dis 205: 772-781.
30. Mbogo CM, Mwangangi JM, Nzovu J, Gu W., Yan G, et al. (2003) Spatial and temporal heterogeneity of Anopheles mosquitoes and Plasmodium falciparum transmission along the Kenyan coast. Am J Trop Med Hyg 68: 734-742.
31. Marsh K, Kinyanjui S (2006) Immune effector mechanisms in malaria. Parasite Immunol 28: 51-60.
32. Goodman AL, Epp C, Moss D., Holder AA, Wilson JM, et al. (2010) New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1. Infect Immun 78: 4601-4612.
33. Biswas S, Dicks MD, Long C.A., Remarque EJ, Siani L, et al. (2011) Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1. PLoS ONE 6: e20977.
34. Draper SJ, Biswas S, Spencer A.J., Remarque EJ, Capone S, et al. (2010) Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J Immunol 185: 7583-7595.
35. McConkey SJ, Reece WH, Moorthy V.S., Webster D., Dunachie S, et al. (2003) Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9: 729-735.
36. Miura K, Orcutt AC, Muratova O.V., Miller LH, Saul A, et al. (2008) Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 26: 193-200.
37. McIntosh RS, Shi J, Jennings R.M., Chappel JC, de Koning-Ward TF, et al. (2007) The importance of human FcgammaRI in mediating protection to malaria. PLoS Pathog 3: e72.
38. Shi J, McIntosh RS, Adame-Gallegos J, Dehal P.K., van Egmond M, et al. (2011) The generation and evaluation of recombinant human IgA specific for Plasmodium falciparum merozoite surface protein 1-19 (PfMSP119). BMC Biotechnol 11: 77.
39. Miura K, Zhou H, Diouf A., Moretz SE, Fay MP, et al. (2009) Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-mero-zoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin Vaccine Immunol 16: 963-968.
40. Malkin EM, Diemert DJ, McArthur J.H., Perreault JR, Miles AP, et al. (2005) Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun 73: 3677-3685.
41. Polley SD, Mwangi T, Kocken C.H., Thomas AW, Dutta S, et al. (2004) Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 23: 718-728.
42. Crompton PD, Kayala MA, Traore B, Kayentao K., Ongoiba A, et al. (2010) A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A 107: 6958-6963.
43. Tran TM, Ongoiba A, Coursen J., Crosnier C, Diouf A, et al. (2014) Naturally Acquired Antibodies Specific for Plasmodium falciparum Reticulocyte-Binding Protein Homologue 5 Inhibit Parasite Growth and Predict Protection From Malaria. J Infect Dis 209: 789-798.
44. Duncan CJ, Sheehy SH, Ewer K.J., Douglas AD, Collins KA, et al. (2011) Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel + CPG 7909. PLoS One 6: e22271.
45. Thompson FM, Porter DW, Okitsu S.L., Westerfeld N., Vogel D, et al. (2008) Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS ONE 3: e1493.
46. Lawrence G, Cheng QQ, Reed C, Taylor D., Stowers A, et al. (2000) Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine 18: 1925-1931.
47. Ockenhouse CF, Sun PF, Lanar D.E., Wellde BT, Hall BT, et al. (1998) Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 177: 1664-1673.
48. Bentebibel SE, Lopez S, Obermoser G., Schmitt N, Mueller C, et al. (2013) Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med 5: 176ra132.
49. Eisen DP, Wang L, Jouin H., Murhandarwati EE, Black CG, et al. (2007) Antibodies elicited in adults by a primary Plasmodium falciparum blood-stage infection recognize different epitopes compared with immune individuals. Malar J 6: 86.
50. Turner L, Wang CW, Lavstsen T, Mwakalinga S.B., Sauerwein RW, et al. (2011) Antibodies against PfEMP1, RIFIN, MSP3 and GLURP are acquired during controlled Plasmodium falciparum malaria infections in naive volunteers. PLoS One 6: e29025.
51. Miura K, Zhou H, Moretz S.E., Diouf A., Thera MA, et al. (2008) Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination. J Immunol 181: 8776-8783.
52. de Cassan SC, Forbes EK, Douglas A.D., Milicic A., Singh B, et al. (2011) The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus. J Immunol 187: 2602-2616.
53. Douglas AD, de Cassan SC, Dicks MD, Gilbert SC, Hill AV, et al. (2010) Tailoring subunit vaccine immunogenicity: Maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine 28: 7167-7178.
54. Hodgson SH, Choudhary P, Elias S.C., Milne KH, Rampling TW, et al. (2014) Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1 - Report on a Phase Ia clinical trial. Mol Ther.
55. Remarque EJ, Roestenberg M, Younis S., Walraven V, van der Werff N, et al. (2012) Humoral Immune Responses to a Single Allele PfAMA1 Vaccine in Healthy Malaria-Naive Adults. PLoS One 7: e38898.
56. Achtman AH, Stephens R, Cadman E.T., Harrison V., Langhorne J (2007) Malaria-specific antibody responses and parasite persistence after infection of mice with Plasmodium chabaudi chabaudi. Parasite Immunol 29: 435-444.
57. Poulsen TR, Meijer PJ, Jensen A, Nielsen L.S., Andersen PS (2007) Kinetic, affinity, and diversity limits of human polyclonal antibody responses against tetanus toxoid. J Immunol 179: 3841-3850.
58. Saul A (1987) Kinetic constraints on the development of a malaria vaccine. Parasite Immunol 9: 1-9.
59. Reddy SB, Anders RF, Beeson J.G., Farnert A., Kironde F, et al. (2012) High affinity antibodies to Plasmodium falciparum merozoite antigens are associated with protection from malaria. PLoS One 7: e32242.
60. Douglas AD, Williams AR, Knuepfer E, Illingworth J.J., Furze JM, et al. (2014) Neutralization of Plasmodium falciparum Merozoites by Antibodies against PfRH5. J Immunol 192: 245-258.
61. Narita M, Yamada S, Matsuzono Y., Itakura O, Togashi T, et al. (1997) Measles virus-specific immunoglobulin G subclass response in serum and cerebrospinal fluid. Clin Diagn Virol 8: 233-239.
62. Kam YW, Simarmata D, Chow A., Her Z, Teng TS, et al. (2012) Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection. J Infect Dis 205: 1147-1154.
63. Chung AW, Ghebremichael M, Robinson H., Brown E, Choi I, et al. (2014) Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med 6: 228ra238.
64. Shi YP, Udhayakumar V, Oloo A.J., Nahlen BL, Lal AA (1999) Differential effect and interaction of monocytes, hyperimmune sera, and immunoglobulin G on the growth of asexual stage Plasmodium falciparum parasites. Am J Trop Med Hyg 60: 135-141.
65. Bouharoun-Tayoun H, Druilhe P (1992) Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect Immun 60: 1473-1481.
66. Tebo AE, Kremsner PG, Luty AJ (2001) Plasmodium falciparum: a major role for IgG3 in antibody-dependent monocyte-mediated cellular inhibition of parasite growth in vitro. Exp Parasitol 98: 20-28.
67. Jepsen MP, Jogdand PS, Singh S.K., Esen M., Christiansen M, et al. (2013) The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas. J Infect Dis 208: 479-488.
68. Jafarshad A, Dziegiel MH, Lundquist R, Nielsen L.K., Singh S., et al. (2007) A novel antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria requires costimulation of monocytes FcgammaRII and FcgammaRIII. J Immunol 178: 3099-3106.
69. Hermsen CC, Verhage DF, Telgt D.S., Teelen K., Bousema JT, et al. (2007) Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine 25: 2930-2940.
70. Groux H, Gysin J (1990) Opsonization as an effector mechanism in human protection against asexual blood stages of Plasmodium falciparum: functional role of IgG subclasses. Res Immunol 141: 529-542.
71. Voice JK, Lachmann PJ (1997) Neutrophil Fc gamma and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble IgG immune complexes. Eur J Immunol 27: 2514-2523.
72. Zhang W, Voice J, Lachmann PJ (1995) A systematic study of neutrophil degranulation and respiratory burst in vitro by defined immune complexes. Clin Exp Immunol 101: 507-514.
73. Miura K, Zhou H, Diouf A., Tullo G, Moretz SE, et al. (2011) Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized. Vaccine 29: 2255-2261.
74. Malkin E, Long CA, Stowers A.W., Zou L., Singh S, et al. (2007) Phase 1 Study of Two Merozoite Surface Protein 1 (MSP1(42)) Vaccines for Plasmodium falciparum Malaria. PLoS Clin Trials 2: e12.
75. Courtin D, Oesterholt M, Huismans H., Kusi K, Milet J, et al. (2009) The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria. PLoS One 4: e7590.
76. Stanisic DI, Richards JS, McCallum F.J., Michon P., King CL, et al. (2009) Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun 77: 1165-1174.
77. Aribot G, Rogier C, Sarthou J.L., Trape JF, Balde AT, et al. (1996) Pattern of immunoglobulin isotype response to Plasmodium falciparum blood-stage antigens in individuals living in a holoendemic area of Senegal (Dielmo, west Africa). Am J Trop Med Hyg 54: 449-457.
78. Ndungu FM, Bull PC, Ross A, Lowe B.S., Kabiru E., et al. (2002) Naturally acquired immunoglobulin (Ig)G subclass antibodies to crude asexual Plasmodium falciparum lysates: evidence for association with protection for IgG1 and disease for IgG2. Parasite Immunol 24: 77-82.
79. Aucan C, Traore Y, Tall F., Nacro B, Traore-Leroux T, et al. (2000) High immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human resistance to Plasmodium falciparum malaria. Infect Immun 68: 1252-1258.
80. Egan AF, Chappel JA, Burghaus P.A., Morris JS, McBride JS, et al. (1995) Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1 (19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum. Infect Immun 63: 456-466.
81. Tongren JE, Corran PH, Jarra W, Langhorne J., Riley EM (2005) Epitope-specific regulation of immunoglobulin class switching in mice immunized with malarial merozoite surface proteins. Infect Immun 73: 8119-8129.
82. Kimani D, Jagne YJ, Cox M, Kimani E., Bliss CM, et al. (2014) Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations. Mol Ther.
83. Douglas AD, Williams AR, Illingworth J.J., Kamuyu G., Biswas S, et al. (2011) The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun 2: 601.